RESUMO
This study was designed to evaluate the possible complications following the use of intraoperative mitomycin-C in patients undergoing surgery for primary pterygium. Hundred eyes of 88 patients with primary pterygium were operated upon using ''bare sclera technique''. Intraoperatively all the patients were applied freshly prepared mitomycin-C 0.02% (0.2 mg/ml) on the bare sclera for a period of 5 minutes, after which the eyes were thoroughly rinsed with a sterile balanced salt solution. Postoperatively, none of the patients recieved mitomycin-C eye drops. After a mean postoperative followup of 14 months, 4 eyes (4%) of 4 patients developed thinning of the sclera with visualization of the underlying uveal tissue. One eye (1%) developed extreme thinning of the sclera with ectasia of the underlying uveal tissue, requiring a scleral patch. Recurrence was seen in 2 eyes (2%) only. The study shows that although intraoperative mitomycin-C (0.02%) reduces the recurrence of pterygium, it leads to serious, cosmetically unacceptable and even sight-threatening complications.
RESUMO
We present a rare case or bee-sting to the cornea which leads to a variety of changes involving the anterior segment of the eye.
RESUMO
To compare the ocular hypotensive efficacy and side effects of either latanoprost or dorzolamide in patients with open angle glaucoma, forty-four patients with open angle glaucoma were included in a randomized, double masked study for a period of 3 months. All previous glaucoma medications were stopped and the patients were randomized to receive either latanoprost 0.005% at bed time or dorzolamide 2% three times daily. After 3 months, the mean reduction in rap was 6.8 (SD 3.1) mm Hg in the latanoprost group as compared to 4.7 (SD 2.4) mm Hg in the dorzolamide group. The difference of 2.1 nun Hg was highly significant. Both the drugs were well tolerated systemically and locally. Latanoprost was superior to dorzolamide in reducing the mean lOP and thus has the potential for becoming the first line treatment in glaucoma.
RESUMO
This study was undertaken to evaluate the long term results 0f intraoperative mitomyc in C appIication in dacryocystorh inostomy (DCR) surgery compared WIith results of the conventiona I procedure. In this prospect were randomly controlled study, a totaI 0f 44 eyes diagnosed with acqu ired nasolacrimal duct obstruction were randomly divided into a conventional DCR group and a mitomyein C group in which mitomycin C was used during DCR surgery. The surgical procedures in both groups were exactly the same. except that in the patients in the mitomycin C group, a piece of neurosurgical cottonoid soaked with 0.2 mg/ml mitomycin C was applied to the osteotom) site for 30 minutes. The results of the DCR surgeries were evaluated by objective findings such as irrigation and the height of tear meniscus and subjective symptoms like condition of tearing Among the 22 eyes in the I n C grou p. 95.45% of patients remained totally symptom free after 9 months 0f follow up; while in the conventional group. 72.72% o("patients were reported to be symptom free and 18% 01" patients to have all improvement ill their symptoms. There was a significant difference between these h\o groups. As far as objective findings were concerned. there were 21 eyes in the mitomycin C group classified as having normal and one eye with moderate tear meniscus level. compared with 16 eyes and 3 eyes. respectivel), in the conventional group. There was also a significant difference between these two groups. The non-patency rate in the mitomycin C group was 4.50/0 compared with II A% in the conventional group. There were no complications such as abnormal nasal bleeding. Thus lucosalnecrosis or infection except one patient with delayed wound healing. Thus intraoperative mitomycin C application was effective in increasing the success rate of DCR surgery in standard nasolarcimal duct obstruction and no significant complications resulted from its use.